Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population

Journal of the American Academy of Dermatology

Volumn 74, Issue 6, 2016, Pages 1057-1065.e4

  Doshi, Jalpa A ^a,b   Takeshita, Junko ^a,b   Pinto, Lionel ^c   Li, Penxiang ^a,b   Yu, Xinyan ^a,b   Rao, Preethi ^b,d   Viswanathan, Hema N ^c   Gelfand, Joel M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adalimumab; adherence; biologic; discontinuation; etanercept; infliximab; Medicare; psoriasis; specialty drug; ustekinumab

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RETREATMENT; RETROSPECTIVE STUDY; SELF REPORT; VERY ELDERLY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FACTUAL DATABASE; GERIATRIC ASSESSMENT; INSURANCE; NEEDS ASSESSMENT; ODDS RATIO; STANDARDS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

AGED; AGED, 80 AND OVER; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; CONFIDENCE INTERVALS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; MEDICATION ADHERENCE; NEEDS ASSESSMENT; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PSORIASIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84959500876     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.01.048     Document Type: Article

References (34)

1. S.K. Kurd, and J.M. Gelfand The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004 J Am Acad Dermatol 60 2 2009 218 224
2. H. Yeung, J. Takeshita, N.N. Mehta, and et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study JAMA Dermatol 149 10 2013 1173 1179
3. A.B. Kimball, C. Jacobson, S. Weiss, M.G. Vreeland, and Y. Wu The psychosocial burden of psoriasis Am J Clin Dermatol 6 6 2005 383 392
4. S.R. Feldman, C. Burudpakdee, S. Gala, M. Nanavaty, and U.G. Mallya The economic burden of psoriasis: a systematic literature review Expert Rev Pharmacoecon Outcomes Res 14 5 2014 685 705
5. A. Menter, A. Gottlieb, S.R. Feldman, and et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 5 2008 826 850
6. B. Chastek, K.M. Fox, C. Watson, and S.R. Gandra Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan Adv Ther 29 8 2012 691 697
7. M. Bonafede, B.H. Johnson, K.M. Fox, C. Watson, and S.R. Gandra Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting J Dermatolog Treat 24 5 2013 369 373
8. Z. Cao, C. Carter, K.L. Wilson, and B. Schenkel Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis J Dermatolog Treat 26 2 2015 113 120
9. Q. Cai, C. Carter, A. AbuDagga, and et al. Real-world dosing and utilization of ustekinumab among patients with psoriasis Am J Pharm Benefits 6 3 2014 129 136
10. J. Takeshita, J.M. Gelfand, P. Li, and et al. Psoriasis in the U.S. Medicare population: prevalence, treatment, and factors associated with biologic use J Invest Dermatol 135 12 2015 2955 2963
11. C. Ryan, N.J. Korman, J.M. Gelfand, and et al. Research gaps in psoriasis: opportunities for future studies J Am Acad Dermatol 70 1 2014 146 167
12. I.S. Grozdev, A.S. Van Voorhees, A.B. Gottlieb, and et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation J Am Acad Dermatol 65 3 2011 537 545
13. A.M. Peterson, D.P. Nau, J.A. Cramer, J. Benner, F. Gwadry-Sridhar, and M. Nichol A checklist for medication compliance and persistence studies using retrospective databases Value Health 10 1 2007 3 12
14. P. Li, M.A. Blum, J. Von Feldt, S. Hennessy, and J.A. Doshi Adherence, discontinuation, and switching of biologic therapies in Medicaid enrollees with rheumatoid arthritis Value Health 13 6 2010 805 812
15. C.R. Harley, J.R. Frytak, and N. Tandon Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate Am J Manag Care 9 6 Suppl 2003 S136 S143
16. B. Tang, M. Rahman, H.C. Waters, and P. Callegari Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis Clin Ther 30 7 2008 1375 1384
17. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 14 2006 1735 1741
18. N.N. Mehta, R.S. Azfar, D.B. Shin, A.L. Neimann, A.B. Troxel, and J.M. Gelfand Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database Eur Heart J 31 8 2010 1000 1006
19. R.S. Azfar, N.M. Seminara, D.B. Shin, A.B. Troxel, D.J. Margolis, and J.M. Gelfand Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis Arch Dermatol 148 9 2012 995 1000
20. J. Wan, S. Wang, K. Haynes, M.R. Denburg, D.B. Shin, and J.M. Gelfand Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study BMJ 347 2013 f5961
21. J. Robst, J.M. Levy, and M.J. Ingber Diagnosis-based risk adjustment for Medicare prescription drug plan payments Health Care Financ Rev 28 4 2007 15 30
22. P. Li, S. McElligott, H. Bergquist, J.S. Schwartz, and J.A. Doshi Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia Ann Intern Med 156 11 2012 776 784 W-263, W-264, W-265, W-266, W-267, W-268, W-269
23. J.A. Doshi, P. Li, and A. Puig Impact of the Medicare Modernization Act of 2003 on utilization and spending for Medicare Part B-covered biologics in rheumatoid arthritis Arthritis Care Res (Hoboken) 62 3 2010 354 361
24. J.M. Donohue, N.E. Morden, W.F. Gellad, and et al. Sources of regional variation in Medicare Part D drug spending N Engl J Med 366 6 2012 530 538
25. P. Li, J.P. Metlay, S.C. Marcus, and J.A. Doshi Factors associated with antimicrobial drug use in Medicaid programs Emerg Infect Dis 20 5 2014 829 832
26. M. Esposito, P. Gisondi, N. Cassano, and et al. Survival rate of antitumor necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study Br J Dermatol 169 3 2013 666 672
27. R. Gniadecki, B. Bang, L.E. Bryld, L. Iversen, S. Lasthein, and L. Skov Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris Br J Dermatol 172 1 2015 244 252
28. S. Curkendall, V. Patel, M. Gleeson, R.S. Campbell, M. Zagari, and R. Dubois Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59 10 2008 1519 1526
29. P. Karaca-Mandic, G.F. Joyce, D.P. Goldman, and M. Laouri Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis Health Serv Res 45 5 Pt 1 2010 1227 1250
30. L. Palmer, S. Abouzaid, N. Shi, and et al. Impact of patient cost sharing on multiple sclerosis treatment Am J Manag Care 4 Special Issue 2012 SP28 SP36
31. S.B. Dusetzina, A.N. Winn, G.A. Abel, H.A. Huskamp, and N.L. Keating Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia J Clin Oncol 32 4 2014 306 311
32. H. Yeung, J. Wan, A.S. Van Voorhees, and et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis J Am Acad Dermatol 68 1 2013 64 72
33. J. Takeshita, S. Wang, D.B. Shin, and et al. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting J Am Acad Dermatol 71 6 2014 1167 1175
34. E.A. Brezinski, and A.W. Armstrong Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy PLoS One 7 4 2012 e33486